EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

What is the future of acromegaly therapy?

Katharina Schilbach iD, Christian J Strasburger iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Katharina Schilbach und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich 80336, Germany. Hauptthemen laut MEDLINE: Acromegaly. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acromegaly is a chronic multisystem disorder in which biochemical control remains suboptimal for many patients. Even when control is achieved, treatment burden is often high despite surgery and a spectrum of established safe and effective therapies. In this narrative review of multinational late-stage clinical trials through October 2025, we summarize drug developments that may broaden individualized medical strategies. Oral somatostatin receptor ligands are now available in the United States, underscoring a shift toward more convenient long-term management. In parallel, non-oral innovations continue to advance. Octreotide subcutaneous depot (CAM2029) maintains biochemical control with acceptable safety and may reduce treatment burden. Emerging pituitary-directed therapy with longer application intervals (Debio 4126) also shows pharmacologic activity consistent with effective disease control. Growth hormone (GH) receptor–directed agents (ALXN2420, MAR002) likewise demonstrate activity aligned with considerable biochemical and clinical benefit. Collectively, these agents may address unmet needs by broadening the scope of options to control production of hepatic insulin-like growth factor I (IGF-I) and to attenuate additional extrahepatic GH signaling. They may also help ease the practical burden of chronic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyHumansOctreotideHuman Growth HormoneInsulin-Like Growth Factor I

Stichwörter der Autor:innen

ALXN2420CAM2029Debio 4126MAR002acromegaly novel therapy

Substanzen

OctreotideHuman Growth HormoneInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich 80336, Germany.
  • Deggendorf Institute of Technology, Faculty of Applied Healthcare Sciences, Deggendorf 94469, Germany.
  • Department of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin 10117, Germany.

ORCID-Profile: Katharina Schilbach, Christian J Strasburger

Zitieren

APA

Schilbach, K., & Strasburger, C. J. (2026). What is the future of acromegaly therapy?. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag144

Vancouver

Schilbach K, Strasburger CJ. What is the future of acromegaly therapy?. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag144

BibTeX
@article{Schilbach2026,
  author = {Schilbach, Katharina and Strasburger, Christian J},
  title = {What is the future of acromegaly therapy?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag144}
}
Kostenlos starten →